Robert Willis

Lutetium-177-labeled prostate-specific membrane antigen radioligand therapy (¹⁷⁷Lu-PSMA-RLT) emerged as a novel treatment for metastatic castration-resistant prostate cancer (mCRPC) following FDA approval in 2022. Its role in metastatic hormone-sensitive prostate cancer (mHSPC) is under active investigation. This systematic review synthesizes evidence on the efficacy, safety, and combinatorial strategies involving ¹⁷⁷Lu-PSMA-RLT in mHSPC.

The deployment of federal armed forces in our cities is creating a new, terrifying reality for communities across the country. Some people may never have suffered anything like it before. But as a Black man who grew up in the South Bronx on the tailwinds of the civil rights era, over-policing is something I’ve experienced my entire life. On January 17, federal agents murdered ICU nurse Alex Pretti on the streets of Minneapolis after he tried to help another protester.